Compare EVCM & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVCM | VERA |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.5B |
| IPO Year | 2021 | 2021 |
| Metric | EVCM | VERA |
|---|---|---|
| Price | $12.01 | $47.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $11.50 | ★ $76.60 |
| AVG Volume (30 Days) | 329.1K | ★ 1.4M |
| Earning Date | 11-06-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $718,038,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.13 | N/A |
| 52 Week Low | $7.66 | $18.53 |
| 52 Week High | $14.41 | $56.05 |
| Indicator | EVCM | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 58.38 | 56.35 |
| Support Level | $10.88 | $45.50 |
| Resistance Level | $12.44 | $50.79 |
| Average True Range (ATR) | 0.54 | 2.43 |
| MACD | -0.08 | -1.17 |
| Stochastic Oscillator | 59.90 | 25.78 |
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. With a platform serving approximately 708,000 customers across three core verticals, including numerous micro-verticals, their solutions address diverse needs within these sectors. Revenue is mostly generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty. The majority of customers contribute modest revenue, with a small percentage contributing higher amounts.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.